---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-015016"
form_type: "8-K"
ticker: "TCMD"
cik: "0001027838"
company_name: "TACTILE SYSTEMS TECHNOLOGY INC"
filed_at: "2021-11-08T23:59:59+00:00"
generated_at: "2026-06-28T11:13:32.334537+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tactile Medical Q3 revenue $52.5M (+7% YoY), net loss $3.4M; cuts FY2021 guidance to $203.5-206M

## Summary
- Q3 revenue $52.5M (+7% YoY); net loss $3.4M ($0.17/share) vs net income $2.4M ($0.12) in Q3 2020.
- Non-GAAP net loss $1.6M; Adjusted EBITDA $4.1M, down from $6.2M a year ago.
- FY2021 revenue guidance cut to $203.5-206.0M (9-10% growth) from prior $216.3-224.5M (16-20%), citing Delta variant and labor shortages.
- Acquired AffloVest respiratory therapy on Sept 8, funded with $30M term loan and $25M revolver draw; AffloVest added $0.9M revenue in Q3.
- Cash $22.4M, total debt $55.0M under credit agreement as of Sept 30, 2021.

## SEC filing metadata
- accession: 0001558370-21-015016
- form_type: 8-K
- ticker: TCMD
- cik: 0001027838
- company_name: TACTILE SYSTEMS TECHNOLOGY INC
- filed_at: 2021-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1027838/000155837021015016/0001558370-21-015016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1027838/000155837021015016/tcmd-20211108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-015016
- JSON: https://secwatch.observer/filing/0001558370-21-015016.json
- Plain text: https://secwatch.observer/filing/0001558370-21-015016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.